Skip to content
DataLookout
Menu

NCT05883163

STIMIT Activator 1 IDE Study

StatusRecruiting
PhaseNot applicable
SponsorStimit AG
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Apr 2026 to Jan 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Study completion pushed from Jul 2026 to May 2027
    • Secondary endpoints revised (3)
    • Site details revised at 2 of 4 sites
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 4 words
  2. Notable Primary completion date: Dec 31, 2024 to Apr 2026v5 Show 8 more changesShow less
    • Start date: Nov 7, 2023 to Jan 24, 2024
    • Primary endpoints revised (2)
    • Eligibility criteria shortened, about 1 word
    • Study sites: 3 to 4
    • Study completion date: Mar 31, 2025 to Jul 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description shortened, about 109 words
    • Study title shortened, about 1 word
  3. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Primary completion date: Feb 5, 2024 to Dec 31, 2024
    • Study sites: 0 to 3
    • Study completion date: Feb 5, 2024 to Mar 31, 2025
    • Start date changed from estimate of Sep 15, 2023 to Nov 7, 2023
    • Study title expanded, about 1 word
  4. Minor Secondary endpoints revised (3)v3
  5. Notable Start date: Jul 5, 2023 to Sep 15, 2023v2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 33 words
    • Primary endpoints revised (2)
    • Secondary endpoints: 1 to 3
    • Study description shortened, about 1 word
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Efffectiveness: Preservation of Diaphragm Thickness
Timeframe: Up to Day 10
Safety: Rate of device or procedure related serious adverse events (SAEs)
Timeframe: Up to Day 10

Secondary (3)

Mechanical Ventilation (MV) Duration
Preservation of Diaphragm Thickness
Time to Rapid Shallow Breathing Index (RSBI) < 105

Arms and interventions

Stimulation GroupExperimental

The intervention group will receive non-invasive stimulation of the phrenic nerve for activation of the diaphragm.

Control GroupNo intervention

The control group will not received intervention and will be treated with standard of care.

Devices: Stimit Activator 1

Sites

4 sites in 2 countries

United States 3, Canada 1